Processing

Please wait...

Settings

Settings

Goto Application

1. AU2014248886 - Compositions and methods for inducing apoptosis

Note: Text based on automatic Optical Character Recognition processes. Please use the PDF version for legal matters

[ EN ]
CLAIMS
What is claimed is:
1. A method of inducing apoptosis in CD20 positive cells, the method comprising:
(i) contacting a population of cells comprising CD20 positive cells with a first complex comprising a targeting moiety and a morpholino, wherein the targeting moiety is an anti-CD20 antibody or an anti-CD20 Fab' fragment, wherein the morpholino of the first complex is 5' GAG TAA GCC AAG GAG AAT CAA TAT A 3'(SEQ ID NO:25); and
(ii) contacting a population of cells with a second complex comprising a copolymer carrier and one or more morpholinos, wherein the one or more morpholinos of the second complex are 5' TAT ATT GAT TCT CCT TGG CTT ACT C 3' (SEQ ID NO:26),
wherein the contacting of the cells with the first complex and the second complex induces apoptosis of the cells.
2.         The method of Claim 1, further comprising repeating step (i) and step (ii).
3.         The method of Claim 1 or Claim 2, further comprising (iii) confirming apoptosis of the cells.
4.         The method of any one of Claims 1 to 3, wherein the cells are B-cells.
5.         The method of any one of Claims 1 to 4, wherein the cells are in a subject.
6.         The method of Claim 5, wherein the subject has non-Hodgkin's lymphoma.
7.         The method of any one of Claims I to 6, wherein the anti-CD20 receptor antibody is IF5, rituximab, tositumomab, ibritumomab, ofatumumab, veltuzumab, ocrelizumab, ocaratuzumab, obinutuzumab, PRO131921, BCD-020, IBI-301, ublituximab, or BLX-301.
8.         The method of any one of Claims I to 7, wherein the morpholino of the first complex and the one or more morpholinos of the second complex are complementary.
9.        A method of inducing apoptosis, the method comprising:
contacting a population of CD20 positive cells with a composition comprising a first complex comprising a targeting moiety and a morpholino, wherein the targeting moiety is an anti-CD20 antibody or an anti-CD20 Fab' fragment, and a second complex comprising a complex comprising a copolymer carrier and one or more morpholinos wherein the morpholino of the first complex is 5' GAG TAA GCC AAG GAG AAT CAA TAT A 3' (SEQ ID NO:25) and wherein the one or more morpholinos of the second complex are 5' TAT ATT GAT TCT CCT TGG CTT ACT C 3' (SEQ ID NO:26), wherein the contacting of the cells with the composition induces apoptosis of the cells.
10. The method of Claim 9, further comprising repeating the contacting of the cells with the composition.
11. The method of Claim 9 or Claim 10, further comprising confirming apoptosis of the cells.
12. The method of any one of Claims 9 to 11, wherein the cells are B-cells.
13. The method of any one of Claims 9 to 12, wherein the cells are in a subject.
14. The method of Claim 13, wherein the subject has non-Hodgkin's lymphoma.
15. The method of any one of Claims 9 to 14, wherein the anti-CD20 receptor antibody is IF5, rituximab, tositumomab, ibritumomab, ofatumumab, veltuzumab, ocrelizumab, ocaratuzumab, obinutuzumab, PRO131921, BCD-020, IBI-301, ublituximab, or BLX-301.
16. The method of any one of Claims 9 to 15, wherein the morpholino of the first complex and the one or more morpholinos of the second complex are complementary.
17. Use of a first complex comprising a targeting moiety and a morpholino in the manufacture of a medicament for inducing apoptosis in CD20 positive cells contacted with a second complex comprising a copolymer carrier and one or more morpholinos, wherein the targeting moiety is an anti-CD20 antibody or an anti-CD20 Fab' fragment, wherein the morpholino of the first complex is 5' GAG TAA GCC AAG GAG AAT CAA TAT A 3' (SEQ ID NO:25), and wherein the one or more morpholinos of the second complex are 5' TAT ATT GAT TCT CCT TGG CTT ACT C 3' (SEQ ID NO:26).
18. Use of a first complex comprising a copolymer carrier and one or more morpholinos in the manufacture of a medicament for inducing apoptosis in CD20 positive cells contacted with a second complex comprising a targeting moiety and a morpholino, wherein the one or more morpholinos of the first complex are 5' TAT ATT GAT TCT CCT TGG CTT ACT C 3' (SEQ ID NO:26), wherein the targeting moiety is an anti-CD20 antibody or an anti-CD20 Fab' fragment, and wherein the morpholino of the second complex is 5' GAG TAA GCC AAG GAG AAT CAA TAT A 3'(SEQ ID NO:25).
19. Use of a first complex comprising a targeting moiety and a morpholino and a second complex comprising a copolymer carrier and one or more morpholinos in the manufacture of a medicament for inducing apoptosis in CD20 positive cells, wherein the targeting moiety is an anti-CD20 antibody or an anti-CD20 Fab' fragment, wherein the morpholino of the first complex is 5' GAG TAA GCC AAG GAG AAT CAA TAT A 3' (SEQ ID NO:25), and wherein the one or more morpholinos of the second complex are 5' TAT ATT GAT TCT CCT TGG CTT ACT C 3' (SEQ ID NO:26).
20.      A kit when used according to the method of any one of claims 1 to 16, the kit comprising:
(i) a first complex comprising a targeting moiety and a morpholino, wherein the targeting moiety is an anti-CD20 antibody or an anti-CD20 Fab' fragment, and wherein the morpholino of the first complex is 5' GAG TAA GCC AAG GAG AAT CAA TAT A 3' (SEQ ID NO:25); or
(ii) a second complex comprising a copolymer carrier and one or more morpholinos, wherein the one or more morpholinos of the second complex are 5' TAT ATT GAT TCT CCT TGG CTT ACT C 3' (SEQ ID NO:26); or
(iii) a composition comprising a first complex comprising a targeting moiety and a morpholino, wherein the targeting moiety is an anti-CD20 antibody or an anti-CD20 Fab' fragment, and a second complex comprising a complex comprising a copolymer carrier and one or more morpholinos wherein the morpholino of the first complex is 5' GAG TAA GCC AAG GAG AAT CAA TAT A 3' (SEQ ID NO:25) and wherein the one or more morpholinos of the second complex are 5' TAT ATT GAT TCT CCT TGG CTT ACT C 3' (SEQ ID NO:26).